The cost implications of prostate cancer screening in the Medicare population-Reference-Cited by-同舟云学术

The cost implications of prostate cancer screening in the Medicare population

Published:2013-10-04 Issue:1 Volume:120 Page:96-102
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Ma Xiaomei¹²,Wang Rong¹²,Long Jessica B.²³,Ross Joseph S.²³⁴,Soulos Pamela R.²³,Yu James B.²⁵,Makarov Danil V.⁶,Gold Heather T.⁷,Gross Cary P.²³

Affiliation:

1. Department of Epidemiology and Public Health; Yale University School of Medicine; New Haven Connecticut

2. Cancer Outcomes; Public Policy and Effectiveness Research Center, Yale University; New Haven Connecticut

3. Department of Internal Medicine; Yale University School of Medicine; New Haven Connecticut

4. Center for Outcomes Research and Evaluation; Yale-New Haven Hospital; New Haven Connecticut

5. Department of Therapeutic Radiology; Yale University School of Medicine; New Haven Connecticut

6. Departments of Urology and Population Sciences; New York University Langone Medical Center, New York University; Department of Urology and Nephrology Section, New York Harbor Veterans Affairs Healthcare System; New York New York

7. Departments of Population Health and Medicine; New York University School of Medicine and New York University Cancer Institute; New York New York

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.28373/fullpdf

Reference34 articles.

1. Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA;Hoffman;BMC Cancer,2005

2. Effect of prostate-specific antigen screening on metastatic disease burden 10 years after diagnosis;Ciezki;Urology,2012

3. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time;Scosyrev;Cancer,2012

4. Screening for prostate cancer: U.S;Moyer;Preventive Services Task Force recommendation statement. Ann Intern Med,2012

5. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement;US Preventive Services Task Force;Ann Intern Med,2008

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival Benefit and Cost Effectiveness of a Future Blood‐Based Diagnostic Test to Detect Cerebral Aneurysm Formation;Stroke: Vascular and Interventional Neurology;2024-01

2. Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP);BMC Health Services Research;2023-06-09

3. Assessment of Care Cascades Following Low-Value Prostate-Specific Antigen Testing Among Veterans Dually Enrolled in the US Veterans Health Administration and Medicare Systems;JAMA Network Open;2022-12-15

4. Low-Value Prostate-Specific Antigen Test for Prostate Cancer Screening and Subsequent Health Care Utilization and Spending;JAMA Network Open;2022-11-22

5. Multiscale analysis of cancer service areas in the United States;Spatial and Spatio-temporal Epidemiology;2022-11